| Literature DB >> 25505833 |
Deise C Friedrich1, Fabiana M de Andrade2, Marilu Fiegenbaum3, Silvana de Almeida3, Vanessa S Mattevi3, Sidia M Callegari-Jacques4, Mara H Hutz1.
Abstract
The Metabolic Syndrome (MetS) is defined as a pattern of metabolic disturbances, which include central obesity, insulin resistance and hyperglycemia, dyslipidemia, and hypertension. Milk has been promoted as a healthy beverage that can improve the management of MetS. Most human adults, however, down-regulate the production of intestinal lactase after weaning. Lactase encoded by the LCT gene is necessary for lactose digestion. The -13910C > T SNP (rs4988235) is responsible for the lactase persistence phenotype in European populations. We herein investigated whether the lactase persistence genotype is also associated with the MetS in subjects from a Brazilian population of European descent. This study consisted of 334 individuals (average age of 41 years) genotyped by PCR-based methods for the -13910C > T SNP. Clinical data were assessed and the genotypes were tested for their independent contribution to the MetS using chi-square tests and multiple logistic regression analysis. Univariate analyses showed that hypertension and MetS prevalence were higher in individuals with the lactase non-persistence genotype than in lactase persistence subjects. Furthermore, lactase persistence was associated with a lower risk for MetS (OR = 0.467; 95% CI 0.264-0.824; p = 0.009). These results suggest that LCT genotypes can be a valuable tool for the management of MetS treatment.Entities:
Keywords: hypolactasia; lactase persistence; lactose; metabolic syndrome
Year: 2014 PMID: 25505833 PMCID: PMC4261958 DOI: 10.1590/S1415-47572014005000012
Source DB: PubMed Journal: Genet Mol Biol ISSN: 1415-4757 Impact factor: 1.771
Demographic, laboratory and clinical characteristics of the investigated sample stratified by genotype.
| Variables | Genotypes | p-value | |
|---|---|---|---|
|
| |||
| CC | CT + TT | ||
| Total number | 163 | 171 | |
| Age (years) | 40.6 ± 14.6 | 42.3 ± 15.6 | 0.444 |
| Gender (% of male) | 47.9 | 46.8 | 0.913 |
| Waist circumference (cm) | 92.1 ± 13.6 | 89.9 ± 11.9 | 0.127 |
| Total cholesterol (mg/dL) | 199.1 ± 45.2 | 198.2 ± 42.9 | 0.902 |
| HDL- cholesterol (mg/dL) | 44.1 ± 10.9 | 44.1 ± 12.4 | 0.798 |
| LDL- cholesterol (mg/dL) | 125 ± 37.9 | 127.3 ± 38 | 0.711 |
| Triglycerides (mg/dL) | 146 ± 111.1 | 131.2 ± 85.2 | 0.418 |
| Glycaemia (mg/dL) | 97.7 ± 30.7 | 92.7 ± 25.3 | 0.081 |
| Hypertension (% of hypertensive individuals) | 22.7 | 13.4 | 0.032[ |
| Physical activity (% of sedentary individuals) | 66 | 61.2 | 0.356 |
| Body mass index (kg/m2) | 26.4 ± 5.13 | 26 ± 4.34 | 0.333 |
| Metabolic syndrome (%) | 34.3 | 21.6 | 0.01[ |
Statistically significant.
CT and TT genotypes were grouped because carriers of the -13910*T allele have the predicted lactase persistence phenotype.
Mann-Whitney U-test.
Student’s t-test.
Chi-square test.
Logistic regression analysis predicting the Metabolic Syndrome.
| OR | 95% CI | p-value | |
|---|---|---|---|
| LP genotype | 0.467 | 0.26–0.82 | 0.009 |
| Age | 1.049 | 1.03–1.07 | < 0.001 |
| Body mass index | 1.247 | 1.16–1.33 | < 0.001 |